Back to journals
Academic Journal

Headache

5 Papers Indexed in Blossom

Data updated

Research Footprint

Headache has 5 tracked papers indexed in Blossom (2021–2025) from 46 authors, most often covering Psilocybin and Ketamine, across Headache Disorders (Cluster & Migraine), Chronic Pain and Safety & Risk Management.

Published Papers

Open Accessindividual

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial

In an exploratory randomised, double‑blind trial in adults with frequent migraine, single or two‑dose psilocybin produced reductions in migraine frequency similar to an active diphenhydramine placebo and no serious adverse events were observed. Incomplete blinding and nonsignificant between‑group differences despite large effect sizes in psilocybin arms indicate the need for larger, better‑controlled trials with headache‑specialist input to separate drug and non‑drug effects.

Published
Journal
Headache
Authors
Schindler, E. A. D., Gottschalk, C. H., Pittman, B. P., D'Souza, D. C.
Open Accessindividual

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study

In an open-label phase Ib ascending-dose study terminated early after enrolling four patients (three completers), low-dose oral psilocybin with psychological support was well tolerated and induced strong subjective altered states and psychological insights, with two participants showing >50% reductions in attack frequency but overall limited effects on headache severity or duration. Cognition could not be assessed acutely due to high subjective dose intensity, and the small sample prevents any conclusive evidence for psilocybin in SUNHA, though the findings suggest psychological factors may be an important treatment target.

Published
Journal
Headache
Authors
Rucker, J., Butler, M., Hambleton, S., Bird, C., Seynaeve, M., Cheema, S., Campbell-Coker, K., Maggio, C., Dunbar, F., Lambru, G., Matharu, M.
Open Accessindividual

CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity

In a small open‑label trial of 10 patients with chronic cluster headache, three oral doses of psilocybin (0.14 mg/kg) were well tolerated and produced a mean 31 per cent reduction in attack frequency, with one patient achieving 21 weeks' remission. Changes in hypothalamic–diencephalic functional connectivity on fMRI correlated strongly with attack reduction (R = −0.81), implicating hypothalamic circuits in the therapeutic response and supporting further clinical study.

Published
Journal
Headache
Authors
Madsen, M. K., Petersen, A. S., Stenbæk, D. S., Sørensen, I. M., Schiønning, H., Fjeld, T., Nykjær, C. H., Larsen, S. M. U., Grzywacz, M., Mathiesen, T., Klausen, I. L., Overgaard‐Hansen, O., Brendstrup‐Brix, K., Linnet, K., Johansen, S. S., Fisher, P. M., Jensen, R. H., Knudsen, G. M.
Paywallindividual

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial

An exploratory randomised, double‑blind, placebo‑controlled trial of a patient‑informed low‑dose psilocybin pulse regimen for cluster headache found no statistically significant reduction in attack frequency overall, although a moderate overall effect size (d = 0.69) and a large, sustained effect in chronic patients (d = 1.25) were observed. Psilocybin was well tolerated, therapeutic effects did not correlate with acute psychotropic intensity, and the authors conclude larger definitive trials are warranted.

Published
Journal
Headache
Authors
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Zhu, Y., Lindsey, H., Pittman, B. P., Cozzi, N. V., D’Souza, D. C., Aarde, S. M.
Open Accessindividual

Intranasal ketamine for acute cluster headache attacks-Results from a proof-of-concept open-label trial

In an open‑label pilot in chronic cluster headache, intranasal ketamine did not meet the predefined 50% pain reduction at 15 minutes but produced a significant mean 59% reduction at 30 minutes (69% of evaluable patients ≤4/10) with no serious adverse events. These results indicate intranasal ketamine may be an effective acute treatment at 30 minutes and warrant larger controlled trials, with caution regarding ketamine’s abuse potential.

Published
Journal
Headache
Authors
Petersen, A. S., Pedersen, A. S., Pedersen, O., Barloese, M. C. J., Holm, P., Jensen, R. H., Snoer, A. H.

Quick Facts

Papers Indexed
5
h-Index
146
Open Access
No
Publisher
Wiley
Country
United Kingdom
Website
Visit